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Properdin (FP) is a positive regulator of the immune system stimulating the activity of the
proteolytically active C3 convertase C3bBb in the alternative pathway of the complement
system. Here we present two crystal structures of FP and two structures of convertase
bound FP. A structural core formed by three thrombospondin repeats (TSRs) and a
TB domain harbors the convertase binding site in FP that mainly interacts with C3b.
Stabilization of the interaction between the C3b C-terminus and the MIDAS bound Mg2+
in the Bb protease by FP TSR5 is proposed to underlie FP convertase stabilization.
Intermolecular contacts between FP and the convertase subunits suggested by the
structure were confirmed by binding experiments. FP is shown to inhibit C3b degradation
by FI due to a direct competition for a common binding site on C3b. FP oligomers are
held together by two sets of intermolecular contacts, where the first is formed by the
TB domain from one FP molecule and TSR4 from another. The second and largest
interface is formed by TSR1 and TSR6 from the same two FP molecules. Flexibility at
four hinges between thrombospondin repeats is suggested to enable the oligomeric,
polydisperse, and extended architecture of FP. Our structures rationalize the effects of
mutations associated with FP deficiencies and provide a structural basis for the analysis
of FP function in convertases and its possible role in pattern recognition.
Keywords: complement, convertase, properdin, complement component C3, crystal structure, regulation, factor B
INTRODUCTION
The complement system is a tightly regulated proteolytic cascade, central to the innate immune
system. It is involved in the detection, phagocytosis and killing of invading pathogens, as well as
clearance of immune complexes. The complement system is furthermore involved in maintenance
of host homeostasis (1) and is important during neural development (2). Activation of the cascade
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depends on recognition of pathogen-associated molecular
patterns or danger-associated molecular patterns on activators
such as pathogens and apoptotic host cells. Activation can occur
through three pathways known as the classical (CP), the lectin
(LP), or the alternative pathway (AP). The point of convergence
is the cleavage of the 186 kDa complement component 3
(C3) generating the C3b fragment (178 kDa) which becomes
covalently associated with the activator surface. C3b can then
associate with the zymogen form of factor B (FB) forming the
AP C3 proconvertase (Figure 1A). C3b bound FB is activated by
the serine protease factor D (FD) forming the smaller fragment
Ba and the larger fragment Bb (60 kDa), which remains non-
covalent associated with C3b. The C3bBb complex is the AP C3
convertase, which catalyzes further C3 cleavage.
Several proteins within the complement system downregulate
the activity of the AP convertase through decay accelerating
activity (convertase dissociation) and cofactor activity, enabling
factor I (FI) degradation of C3b into iC3b. In contrast, properdin
(FP) is a direct positive regulator of the AP and stabilizes
the convertase by associating with C3b in the convertase and
proconvertase, reviewed (3). The function and importance of FP
in host immunity is illustrated by the severity of disease in X-
linked FP deficiencies giving rise to three different phenotypes
(4). The hallmark of type I deficiency is a complete lack of
FP, type II results in a low level of FP in plasma and type
III is characterized by a dysfunctional FP present at a plasma
concentration in the normal range (5). All three types of
deficiencies are characterized by low serum AP activity and
increased susceptibility to meningococcal infection and sepsis
(6). FP deficiencies may also be related to autoimmune diseases
such as systemic lupus erythematosus (7).
It has been predicted for 30 years that the majority of FP is
organized in six thrombospondin repeats (TSRs) (8). The nascent
FP monomer is secreted into the endoplasmic reticulum where
it undergoes extensive posttranslational modification adding up
to 15 C-linked, one N-linked and four O-linked glycans to the
polypeptide chain (9, 10). FP oligomerizes prior to secretion,
and in plasma it is found in a mass distribution with roughly
25% tetramers, 50% trimers and 25% dimers (11, 12). FP is
produced predominantly by monocytes, T-cells and neutrophils
and circulates in plasma at ∼4–25µg/ml (13). The capability
of stimulating the alternative pathway increases strongly with
oligomer size (11).
Numerous crystal and electron microscopy (EM) structures
determined the last two decades have provided a comprehensive
structural framework that now underlies the mechanistic
understanding of the complement system and supports the
development of therapeutic strategies aiming at complement
modulation, reviewed in Morgan and Harris (14) and Schatz-
Jakobsen (15). But, the oligomerization and polydispersity of
FP complicate structural studies. Classic studies conducted with
negative stain EM revealed that FP oligomers are extended
structures organized in cyclic dimers, trimers, and tetramers in
which doughnut shaped vertexes formed by two protomers are
connected by thin flexible structures (16). Solution scattering of
FP indicated a maximum extent of 25 and 30 nm for the FP
dimer and trimer, respectively (17). Recently, a more detailed
FIGURE 1 | The function and structure of FP. (A) In the complement
alternative pathway FP bound C3b can bind FB forming the C3bB(P) AP C3
proconvertases. The serine protease FD can then cleave zymogen FB resulting
in the AP C3 convertase C3bBb(P). According to nomenclature, the letter “F”
is skipped in complexes of complement proteins. (B) Cartoon of the FPc and
FPc13 constructs. The domains are indicated by a thick arrow in the color
corresponding to the specific domain. (C) A surface representation of the FPc
crystal structure with TB domain and TSR coloring as in panel B. (D) Overlay
of the structures of FPc (blue) and FPc13 (gray) shown in a cartoon
representation demonstrating the flexibility of the TSR2 domain. (E) A cartoon
representation of the interface in FP between TSR5 (light blue) and TSR6 (navy
blue). Residues important for the interface are shown as sticks. (F) Theoretical
model of a FP dimer with the monomers colored gray and blue, respectively.
The dashed line outlines one FPc molecule for comparison with panel C.
negative stain EM study using oligomeric FP confirmed the
presence of cyclic oligomers. Furthermore, it was observed that
each FP vertex contains one binding site for the AP C3 convertase
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and it was suggested that the FP vertex contacts both C3b and
Bb (18).
Due to the polydispersity and flexibility of FP observed by
EM, we recently engineered a recombinant oligomeric FP from
which a functional monomer called FPc could be excised by
specific proteolysis. This was accomplished by insertion of a
cleavage site for the TEV protease between the third and fourth
FP thrombospondin repeats (12). This location of the cleavage
site was based on prior results demonstrating that FP with
the third thrombospondin repeat deleted forms oligomers and
stabilize the C3bBb convertase (19). The functional monomer
FPc encompass residues 28–255 (the head fragment) from one
monomer and residues 256–469 (the tail fragment) from a second
monomer (Figure 1B). Using FPc, we showed by low resolution
crystallography that FP mainly contacts C3b in the convertase
C3bBb (12, 18) in accordance with the results presented in
Alcorlo et al. (18). However, in the absence of an atomic model
of FP, identification of FP and convertase residues in contact
and the exact organization of the FP monomers and oligomers
remained unsettled. Here we present the first atomic structures of
FP allowing us to describe the contacts between two FPmolecules
responsible for oligomer formation and to propose an atomic
model for the FP-C3bBb complex.
MATERIALS AND METHODS
Protein Production
Properdin
TEV protease cleavable FP was expressed from a stably
transfected HEK293F cell line generated as described in Pedersen
et al. (20). WT FP was expressed by transient expression
in HEK293F cells as described in Pedersen et al. (12). WT
FP and FPc generated from TEV cleavable FP were both
purified as described (12). His-tagged FPc and FPc13 used
for crystallization were expressed and purified from HEK293F
cell supernatants as described (20). DNA encoding the FP TB-
TSR3 head fragment (FPh) and TSR4-6 tail fragment (FPt)
was synthesized (GenScript) with the endogenous FP signaling
peptide and a 6His-tag at the C-terminus of FPt. FPh and FPt
were then cloned into separate pCEP4 mammalian expression
vectors using HindIII and BamHI restriction sites. Constructs
encoding FP TB-TSR1 (FPh12,3) and TB-TSR2 (FPh13) were
generated from FPh by insertion of a stop codon between TSR1
and TSR2 or TSR2 and TSR3, respectively, by site-directed
mutagenesis. In the FPh12,3 construct C132 was mutated to
Ala to avoid a free cysteine. Co-transfection of FPh, FPh13, or
FPh12,3 with FPt results in the expression of FPht, FPht13,
and FPht12,3, respectively. FPht, FPht13 and FPht12,3 were
expressed by transient transfection of HEK293F cells as described
(12). FPht variants and FPht13 and FPht12,3 were purified from
cell supernatants as described (20).
Native C3, C3b, biotin-C3b, hC3Nb1, FB, miniFH, FH,
FI, and FD
Native C3 was purified from outdated plasma pools as described
previously (21). The native C3 used for crystallization was
obtained by a final size exclusion chromatography (SEC)
purification step on a Superdex200 increase 24mL (GE
Healthcare) in 20mM HEPES, 150mM NaCl pH 7.5. C3b
was generated by trypsination of native C3 and purified
as described in Pedersen et al. (12). Biotinylated C3b was
generated from C3 with 10 fold molar excess of Maleimide-
PEG2-Biotin reagent being present during the cleavage of
native C3. The generated C3b further was incubated with the
Maleimide-PEG2-Biotin reagent for 6 h on ice after cleavage
before being purified by cation exchange. hC3Nb1 was expressed
and purified as described (21). A codon optimized version
of the miniFH construct similar to that in Schmidt et al.
(22) was synthesized (GenScript) with a C-terminal TEV-site
followed by a 6His-tag and inserted into pcDNA3.1. MiniFH
was expressed in HEK293F cells after PEI transfection and
purified by affinity chromatography followed by anion-exchange
on a 1mL Source15Q column equilibrated in 20mM Tris pH
8.8. The miniFH was eluted by a linear gradient from 50 to
400mM NaCl. A final polishing SEC step was performed on
a 24mL Superdex200 increase equilibrated in 20mM HEPES,
150mM NaCl pH 7.5. FB variants K348A, L349A, K350A were
generated by site directed mutagenesis using FB D279G, S699A
as template. Recombinant FB D279G, S699A and FB D279G,
S699A, K348A, L349A, K350A were expressed and purified from
HEK293F cells as described (12). FD, FI, and FH were obtained
from Complement Technology.
Selection and Production of hFPNb1
One llama (Lama glama) was immunized 4 times with FPc (400
µg) to generate a robust immune response. Blood was collected
and shipped to Aarhus University where peripheral blood
lymphocytes were isolated and used for total RNA extraction
using the RNase Plus Mini Kit (Qiagen). cDNA encoding
VHHs was generated using the SuperScript III First-Strand Kit
(Invitrogen) with random hexamer primers and amplified by
PCR using primers specific for the VHH genes. The PCR product
was subsequently cloned into a pCANTAB phagemid vector for
phage display. The M13 phage-display Nb library was generated
using the trypsin cleavable M13KO7trp helper phage. Selection
was performed with 1 µg of FPc coated in a microtiter well.
Competitive elution was performed by adding 100 µL of 1
mg/mL polyclonal goat anti-FP Ab (Complement Technology)
in PBS. After 30min, the well was washed thrice with PBS and
the remaining phages were eluted using trypsin (10µg/mL in
PBS) for 30min at 37◦C. The eluted phages were then added
to 0.9mL mid-log phase E. coli TG1 culture (OD600 0.4–0.5)
for infection at 37◦C for 1 h. Bacteria were grown overnight at
30◦C and harvested for phage amplification and a second round
of selection performed with 0.1 µg of FPc. After two rounds of
selection, single colonies were transferred to a 96-well plate where
Nb-pIII was expressed at 30◦C overnight using 1mM IPTG. The
96-well plate was subsequently centrifuged and the supernatant
was analyzed by ELISA. MaxiSorp microtiter wells (Nunc) were
coated with 1 µg FPc overnight and blocked for 1 h with 2% w/v
BSA/PBS. 50 µl supernatant were then transferred to each well
and incubated for 1 h. The wells were subsequently washed with
PBS-T and 50 µl HRP-anti-E-tag mAb diluted 1:5,000 in 2% w/v
BSA/PBS was added. After 1 h incubation, the wells were washed
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with PBS and 100 µL TMB (Thermo Scientific) was added to
each well. The reaction was stopped with 50 µL 1M H2SO4 and
the plate was read at OD450 and OD650. Positive clones were
subcloned into the pET-22b(+) expression vector for bacterial
expression. hFPNb1 was subsequently expressed and purified as
described in Jensen et al. (21).
Complement Deposition
To assay the effect of hFPNb1 on AP activity microtiter wells
were coated with zymosan (2µg/mL in 50mM sodium carbonate
buffer, pH 9.6) and washed thrice with TBS containing 0.1%
Tween 20 (TBS-T) before blocking wells with 1 mg/mL HSA
in TBS-T. Fifty µL sample containing 0.007–714 nM hFPNb1 in
NHS diluted 1:10 in VBS/EGTA/Mg2+ buffer (5mM barbital, pH
7.4, 145mM NaCl, 10mM EGTA, 5mM MgCl2) was added to
each well and the plates were incubated at 37◦C for 1 h. A control
experiment was performedwithNHS diluted in VBS/EDTA (VBS
supplemented with 10mM EDTA). After incubation, wells were
washed thrice with TBS-T and 50 µL of 0.75µg/mL biotin-
anti-hC3c (Dako) in TBS-T was added to each well and plates
incubated overnight at 4◦C. The following day, wells were washed
thrice with TBS-T before 50 µL of 1µg/mL Europium-labeled
streptavidin (Perkin-Elmer) in TBS-T supplemented with 25µM
EDTA was added to each well and incubated for 1 h at room
temperature. The wells were then washed with TBS-T, and 50
µL DELFIA enhancement solution (Perkin-Elmer) was added to
each well. The plates were vortexed vigorously and incubated for
2min before time-resolved fluorescence was measured at 615 nm
with a VICTOR5 plate reader (PerkinElmer).
X-ray Structure Determination
Crystallization of FPc and FPc13 and the data quality have
been described elsewhere (20) and details for C3bBbSCIN-
FPc crystallization and data collection were also described
(12). A sulfur-SAD data set was obtained from two crystals
of FPc13 at the Petra III P13 beamline with a helium path
inserted between the crystal and the detector. Crystals of the
C3bBbSCIN-FPht13-hFPNb1 complex were obtained by vapor
diffusion against a reservoir solution containing 100mM NaCl,
5% (w/v) PEG4000, 10mM MgCl2, 100mM Sodium Cacodylate
trihydrate pH 5.8. Crystals of hFPNb1 were obtained by vapor
diffusion of 450 nL drops mixed in a 1:2 ratio with a reservoir
containing 13.1% (v/v) MPD, 13.1% PEG1000 (w/v) 13.1%
(w/v) PEG3350, 100mM Tris Bicine pH 8.5, 33mM CaCl2,
33mM MgCl2, 4% (v/v) formamide, 114mM FOS-Choline 8.
Crystals of C3bBbSCIN-FPht13-hFPNb1 were cryoprotected by
soaking in reservoir solution supplemented with 25% glycerol
whereas hFPNb1 crystals were cryoprotected directly in reservoir
solution prior to data collection at Petra III. Native C3 at
a final concentration of 8 mg/mL was added 1.5 fold molar
excess of hC3Nb1 and crystallized by vapor diffusion of 200
nL drops mixed in a 1:1 ratio with a reservoir containing
100mM HEPES pH 7.2, 1.75% (w/v) PEG8000. The crystals
were cryoprotected in reservoir solution supplemented with 30%
glycerol prior to data collection at Petra III. All diffraction
data (Supplementary Table 2) were processed with XDS (23).
The FPc13 structure was determined by molecular replacement.
Electron densities for the C3bBbSCIN-FPc complex (12) and the
C3bBbSCIN-FPht13-hFPNb1 complex (this study) calculated
without contribution from FP models were improved by multi
crystal averaging with phenix.multi_crystal_average (24). The
resulting density was used for constructing a poly-alanine
model for TSR1 and TSR4-6 based on known structures of
TSRs, while multiple model secondary structure fragments were
placed into density for the TB domain. This polyalanine model
was used to isolate a density based search model roughly
encompassing the TSR1, TSR5, TSR6, and the TB domain with
phenix.cut_out_density (24). Molecular replacements solutions
for the FPc13 native data (20) and the FPc13 sulfur SAD data
(Supplementary Table 2) were identified with phenix.phaser
(25) and subjected to density modification with 81% solvent.
After improvement with phenix.multi_crystal_average over the
two different FPc13 crystals, the resulting phases were used
to identify sulfur sites in the anomalous data. Although a
pure experimental map calculated with phenix.autosol by SAD
phasing and density modification starting from these sites
revealed the outline of FPc13, the inclusion of these phases
did not improve the electron density compared to the MR
based multi crystal averaging map already obtained. However,
most of the disulfide bridges in the TB and TSR domains
could be mapped to the sulfur sites identified in the anomalous
data. An iterative process involving rebuilding in Coot (26)
and refinement with phenix.refine (27) provided an initial
model containing all FPc13 domains. The TB domain fold and
disulfide bridge arrangement were confirmed through a DALI
search (28). This FPc13 model was then used for molecular
replacement into the 2.8 Å FPc data, and a complete model
for FPc was build and refined in an iterative manner. The
structure of hFPNb1 was determined by molecular replacement
followed by rebuilding and refinement. The final model of FPc
was placed manually into the density modified maps of the
C3bBbSCIN-FPc and C3bBbSCIN-FPht13-hFPNb1 complexes.
In the latter complex, clear omit density allowed the docking
of the refined hFPNb1 structure. The resulting models of the
two complexes were refined with phenix.refine using rigid
body and TLS refinement, positional refinement under NCS
restraints, and grouped B-factor refinement. Side chains at
the FP-convertase interface were remodeled if the associated
main chain was altered or clashes occurred, but to avoid bias
side chains were not fitted in detail to point toward putative
interaction partners. The structure of the C3-hC3Nb1 complex
was determined using the coordinates of the C3 structure (PDB
entry 2A73) with the C345c domain removed for molecular
replacement in phenix.phaser. The coordinates of hC3Nb1
(RCSB entry 6EHG) and the C345c domain (RCSB entry 2A73)
were manually placed in Coot. The model was then refined
against the reflections with rigid body, TLS and grouped B-
factor refinement in phenix.refine. In an iterative manner the
structure was subjected to cycles of manual rebuilding in coot
followed by positional, grouped B-factor and TLS refinement
in phenix.refine. Prior to final refinement the structure was
fitted to the electron density map using iMDFF as described
in Croll and Andersen (29). Diffraction data and atomic
models are available at the protein data bank as entries
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6RUS, 6SEJ, 6RUR, 6RU3, 6RUV, 6RU5, 6RV6 as specified in
Supplementary Tables 1, 2.
Mass Spectrometry
Purified FPc13 in 50mM ammonium bicarbonate, 5mM
iodoacetamide was heated to 60◦C for 10min in the presence
of 0.1% (v/v) of the RapiGest (Waters) denaturant, allowed
to cool and subsequently digested at 37◦C for 16 h by the
addition of porcine trypsin (1:20). The digest was acidified by
the addition of 0.5% trifluoroacetic acid and incubated at 37◦C
for 1 h to allow RapiGest degradation. The generated peptides
were separated by UPLC reverse-phase chromatography on a
BEH300 C18 column (2.1mm × 15 cm; 1.7µm) operated by
an Aquity UPLC system (Waters). The column was run at 300
µL/min using a 1% B/min linear gradient of solvent B (90%
acetonitrile, 0.08% (v/v) trifluoroacetic (TFA) in solvent A (0.1%
(v/v) TFA). Fractions were collected manually and analyzed by
MALDI mass spectrometry on a Bruker Autoflex III instrument
operated in linear mode and calibrated in the mass range of 5,000
Da to 17,500 Da using Protein calibration standard I (Bruker
Daltronics). The analysis was performed in linear mode to enable
the detection of disulfide-linked peptides.
FH-Assisted FI Cleavage Assay
High capacity streptavidin agarose beads (Thermo Scientific)
were saturated with biotinylated C3b, yielding ∼8 µg of C3b
per µL of settled streptavidin beads. The streptavidin beads were
added 4% (w/w) FH and 2-fold molar excess of oligomeric FP
as compared to C3b. The beads were incubated for 30min on
ice before 1% (w/w) of FI compared to C3b was added. The
reactions were incubated at 37◦C and samples were taken after
15, 30, 60, and 120min, and analyzed by SDS-PAGE. The ratio
of the C3b α’ chain and streptavidin was quantified from three
independent experiments using ImageJ (30). The FP used in this
assay was∼50% dimer and 50% trimer as judged by SEC analysis
performed on a 24mL Superdex200 increase.
Bio-Layer Interferometry Assays
Bio-layer interferometry experiments were performed on an
Octet Red96 (ForteBio) at 30◦C and shaking at 1,000 RPM. For
the FP/FH competition assay, miniFHwas immobilized on amine
reactive sensors (AR2G, ForteBio). The sensors were equilibrated
in H2O for 5min before being activated in a mixture of 20mM 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide and 10mM N-
hydroxysuccinimide for 5min. MiniFH was then loaded at
20µg/mL in 10mM sodium acetate, 100mM NaCl pH 5.0 for
10min before the sensors were quenched with 1M ethanolamine
for 5min. The sensors were equilibrated in the assay buffer (PBS
supplemented with 1 mg/mL BSA and 0.05% Tween 20) for
5min. The association of either FP alone (94 nM), C3b (280 nM),
or a mixture of FP and C3b (94 and 280 nM, respectively) were
assessed for 60 s followed by a 60 s dissociation step in assay
buffer. The assay was repeated twice after regeneration of the
sensors using PBS supplemented with 4M of NaCl. The FP used
for the assay was ∼90% dimer and 10% trimer as judged by SEC
analysis performed on a 24mL Superdex200 increase. For kinetic
analysis hFPNb1 mutants were immobilized on Anti-Penta-HIS
sensors (HIS1K, ForteBio). The sensors were equilibrated in
assay buffer (PBS supplemented with 1 mg/mL BSA and 0.05%
Tween 20) for 5min before the sensors were conditioned by
running a regeneration cycle consisting of three sub-cycles of 5 s
in 100mM glycine pH 2.5 followed by 5 s in assay buffer. The
sensors were subsequently equilibrated for 60 s in assay buffer
before being loaded with 50µg/mL of hFPNb1 variant in assay
buffer for 120 s. The sensors were then equilibrated in assay buffer
for 60 s followed by an association phase of 120 s with FPc at
189, 94.5, 47.3, 23.6, 11.8, or 5.9 nM. This was followed by a
120 s dissociation step in assay buffer. The sensors were then
subjected to a new round of regeneration before being used for
a new round of kinetics. The experiment was first performed
with hFPNb1, followed by hFPNb1 I103A, hFPNb1 I103A,
L104A, and hFPNb1 I103A, L104A, V105A, respectively. The
kinetic constants were determined using non-linear regression
in GraphPad Prism. A 1:1 Langmuir binding model was applied
where the association is modeled as R(t) = Req(1-exp(-kobs·t),
kobs = kon·[FPc]+koff, Req = Rmax([FPc]/([FPc]+KD), KD
= koff/kon; and the dissociation is modeled as a first order
exponential decay, R(t) = R(120)·exp(-koff(t-120s). For the
BLI assay assessing the ability of FPht variants to bind C3b,
biotinylated C3b was immobilized on streptavidin sensors (SA,
ForteBio). The sensors were equilibrated in assay buffer (20mM
MES pH 6.0, 100mM NaCl, 0.05% Tween, 1 mg/mL BSA) for
5min. The sensor were then loaded with biotinylated C3b at
16µg/mL for 10min, before being equilibrated in assay buffer
for 240 s. The association of 100µg/mL FPht WT or mutants
(R329A, R330A, Q343R, R351A, R353A, R359A, Q364A, Q365A,
Q364A/Q365A, Y414D) were then assessed in a 120 s association
step followed by a 120 s dissociation step in assay buffer. Two
independent but identical experiments were performed. The Req
was determined as the average response from 80 to 120 s. The
experiment quantifying the binding affinity of FPht WT, FPht
R353A, FPht Q343R, and FPht Y414D was performed identically
but with the association and dissociation steps reduced to 60 s
and using FPht variants used at 100, 50, 25, 12.5, 6.25, 3.13, and
1.56µg/mL. Due to the low level of binding of the FPht mutants
the KD was determined using steady state kinetics, by non-linear
fitting in GraphPad Prism. A 1:1 binding model was applied
where the Req was modeled as Req = RmaxC/(C+KD). The Req
was determined as the average response from 40 to 60 s during
the association phase. The KD determined for FPht WT was very
similar using steady state analysis (320 nM) and kinetic analysis
using the integrated rate equations (350 nM).
For the assay analyzing the binding of FPht to C3b—
FB (D279G, S699A, K348A, L349A, K350A), hFPNb1 was
immobilized on amine reactive sensors (AR2G, ForteBio). The
sensors were equilibrated in H2O for 5min before being activated
in a mixture of 20mM 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide and 10mM N-hydroxysuccinimide for 5min.
hFPNb1 was then loaded at 20µg/mL in 10mM sodium acetate
pH 5.0 for 10min before the sensors were quenched with 1M
ethanolamine for 5min. The sensors were equilibrated in the
assay buffer (20mM MES pH 6.0, 100mM NaCl, 0.05 % Tween,
1 mg/mL BSA, 5mM MgCl2) for 5min, before FPht (20µg/mL)
was loaded. The association of 50µg/mL C3b, 50µg/mL FB
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(D279G, S699A), 50µg/mL FB (D279G, S699A, K348A, L349A,
K350A), 50µg/mL C3b + 50µg/mL FB (D279G, S699A), or
50µg/mL C3b + 50µg/mL FB (D279G, S699A, K348A, L349A,
K350A) was assessed for 120 s, followed by 120 s of dissociation
in assay buffer. The signal for FB (D279G, S699A, K348A,
L349A, K350A) or FB (D279G, S699A) were subtracted for
their respective experiment in complex with C3b. A control
experiment was performed where the FB (D279G, S699A) and
FB (D279G, S699A, K348A, L349A, K350A) binding to a C3b
coated streptavidin sensor was tested (SA, ForteBio). The sensors
were equilibrated in assay buffer (20mM MES pH 6.0, 100mM
NaCl, 0.05% Tween, 1 mg/mL BSA, 5mMMgCl2) for 5min. The
sensor were then loaded with biotinylated C3b at 16µg/mL for
10min, before being equilibrated in assay buffer for 240 s. The
association of 40µg/mL FB (D279G, S699A) or 40µg/mL FB
(D279G, S699A, K348A, L349A, K350A) where then assessed in
a 120 s association step followed by a 120 s dissociation step in
assay buffer.
Analysis of FP Folding and Expression
HEK293F cells were co-transfected with either FPh L47A +
FPt, FPh L58A + FPt, FPh L47A, L58A + FPt, FPh + FPt
L275A, FPh L47A, L58A + FPt L275A, FPh + FPt L456A,
FPh L47A, L58A + FPt L456A, FPh C32Y + FPt, FPt, FPh,
FPh + FPt, or WT FP in a total of 50mL per transfection.
The cells were harvested after 4 days by centrifugation at
200 ×g, and the cell pellet were frozen. The cell supernatants
were centrifuged at 6,000 g and subsequently filtered through
a 0.22µm filter. The cell pellets were thawed and resuspended
in 30mL of 25mM Tris, 150mM NaCl pH 7.6, 1% (w/v)
nonyl phenoxypolyethoxylethanol, 1% sodium deoxycholate,
0.1% (w/v) SDS, 1mM phenylmethylsulfonyl fluoride and 5mM
EDTA. The cells were lyzed by sonication, the cell debris
was removed by centrifugation at 14,000 g for 10min and the
supernatant was filtered through a 0.22µm filter. Total protein
content was determined by a Bradford assay (BioRad) using BSA
as a standard to quantitate protein content of samples. This was
used to normalize the sample volume loaded on a 4–20% SDS-
PAGE (GenScript) of both the cell pellet and cell supernatant.
PVDF membranes were activated in 96% ethanol for 5min and
the protein was blotted from the SDS-PAGE gel onto amembrane
in 25mMTris, 192mM glycine, 20% (v/v) ethanol, pH 8.3, for 1 h
at 100V. The blots were blocked for 1 h in PBS-T supplemented
with 3% BSA and subsequently washed for 5min in PBS-T. The
blots were incubated O/N in PBS-T added primary antibody at
4◦C. The blot containing the cell pellet was added rabbit anti-
GAPDH antibody (Santa Cruiz Biotechnology) diluted 1:2,000
and the blot containing the cell supernatant was added mouse
antiHis mAb (GenScript) diluted 1:4,000. The blots were washed
thrice for 5min in PBS-T and subsequently incubated for 1 h at
room-temperature in PBS-T added secondary antibody. For the
blot containing the cell pellet goat anti-rabbit HRP-conjugated
antibody (Sigma-Aldrich) diluted 1:20,000 was added and for the
blot containing the cell supernatant anti-mouse HRP-conjugated
antibody (Jackson ImmunoResearch) diluted 1:15,000 was added.
The blots were then washed thrice in PBS-T before being added
SuperSignal West dura extended duration substrate (Thermo
Scientific) for 5min. The blots was developed on X-ray film.
Analysis of FP E244 Mutations
FP mutants E244K, E244A, E244R, and E244Q were generated
by site directed mutagenesis using the QuickChange Lightning
kit (Agilent technologies) and the pCEP4:FP construct described
in Pedersen et al. (12) as template. WT FP and FP mutants were
transfected into 100mL HEK293F cells as described (12). The
cells were harvested and the supernatants were filtered using
0.22µm filters. The pH was adjusted by addition of 20mM Tris
pH 8.0. Fifty µg of hFPNb1 were added to each supernatant and
incubated for 2 h at room temperature. Twenty-five µL of Ni-
NTA beads were then added and the samples were incubatedO/N
at 4◦C. The beads were transferred to 1mL spin columns (Biorad)
and the beads were washed thrice with 500µL of 100mMHEPES,
500mM NaCl, 10mM imidazole pH 7.5. The bound hFPNb1
complexes were subsequently eluted in 300 µL of 100mM
HEPES, 500mM NaCl, 400mM imidazole pH 7.5. Eluates were
retrieved by centrifugation at 70 g for 30 s and subsequently
reapplied to the column before another centrifugation step was
performed. The eluted FP variants as well as plasma purified
FP (Complement Tech) were applied to a 24mL Superdex200
increase equilibrated in 20mM HEPES, 150mM NaCl, pH 7.5.
Fractions of 250 µL were collected throughout the run and
every second fraction from 8mL until 13mL was analyzed
by western blotting. The samples were loaded on a 4–20%
SDS-PAGE (GenScript) and were subsequently transferred to a
nitrocellulose membrane. The membrane was blocked O/N at
4◦C in MPBS (PBS supplemented with 2% (w/v) skimmed milk
powder). The membrane was then added goat anti-human FP
antibody (Complement Technology) diluted 1:2,000 in MPBS for
3 h at room temperature. The membrane was washed in PBS-T
followed by two washes in PBS for 5min each. Rabbit anti-goat
HRP-conjugated antibody (Sigma-Aldrich) diluted 1:2,000 in
MPBS was added and incubated for 2 h at room temperature. The
membrane were then washed thrice in PBS-T before being added
SuperSignal West dura extended duration substrate (Thermo
Scientific) for 5min. The blots was developed on X-ray film.
Patient Data
A patient with a FP deficiency was identified in the Complement
Diagnostic Laboratory at the HEGP hospital in Paris (with
informed consent from the patient’s parents for the genetic
analyses) using direct sequencing. Complement analysis was
performed in the plasma of the patient and his relatives. A
CH50 test to evaluate the activity of the classical complement
pathway was performed on sheep IgG-opsonized erythrocytes.
An AP50 test to evaluate the alternative pathway activity was
carried out on rabbit erythrocytes. Plasma C3 and C4 were
quantified using nephelometry (Dade Behring, Deerfield, IL,
USA). The levels of FP were evaluated by ELISA. All analyses
were performed according to the routine diagnostic procedures
of the Complement Diagnostic Laboratory at the HEGP hospital
in Paris.
Frontiers in Immunology | www.frontiersin.org 6 August 2019 | Volume 10 | Article 2007
Pedersen et al. Structure of Human Properdin
Molecular Dynamics Simulations
As starting point for our simulations, crystal structures of C3
(PDB entry 2A73) and C3b (PDB entry 5FO79) were placed
into a rhombic dodecahedron box, solvated with TIP3P water
molecules containing Na+ and Cl− ions at 100mM, resulting in
∼371,000 atoms in the C3model, and∼449,000 atoms in the C3b
model. The disulfide bonds present in the crystal structures were
maintained. The CHARMM36m force field (31) was used for
both protein and ions. Simulations were performed in the NPT
ensemble (298K, 1 bar) using the V-rescale thermostat (32) with
a 1 ps coupling constant, and the Parrinello-Rahman barostat
with a 2 ps time coupling constant. A cut-off of 1.0 nm for both
the van der Waals interactions and the short-range electrostatic
interactions, with long-range electrostatics treated using PME.
Neighbor searching was performed every 10 steps. We employed
the hydrogen mass repartitioning technique (33) with a single
LINCS iteration (expansion order 6) (34) and constrained the
bonds involving hydrogen atoms using the LINCS algorithm,
allowing simulations to be performed with an integration time
step of 5 fs. All MD simulations were performed using Gromacs
2016.3 (35). One microsecondMD simulation was performed for
both C3 and C3b. The root mean square fluctuation (RMSF) was
used to quantify the flexibility of the proteins. To measure the
dynamics of the whole C345c domain, the RMSF profiles were
calculated from the trajectories aligned on the C3/C3b β-chain.
Tomeasure the intra-domain dynamics of the C345c domain, the
RMSF profiles were calculated from the trajectories aligned on
the central β-sheet of the C345c domain (residue 1544–1610). For
a better visualization of the residue fluctuations of C345c domain,
the residue RMSF values were mapped onto the corresponding
crystal structures of the C345c domain in C3 and C3b.
RESULTS
Structure Determination and Description of
FP
To elucidate the detailed structural organization of FP, we
determined the crystal structures of the functional properdin
monomer FPc earlier described by us (12) at 2.8 Å. We
also determined the structure of the FPc13 protein at 3.5
Å of resolution where the third thrombospondin repeat
(TSR3) is removed by proteolysis of TEV sites inserted
at the TSR2-TSR3 and the TSR3-4 junctions in FP (20).
The quality of the diffraction data was previously reported
in Pedersen et al. (20). The two structures agree in all
aspects including post-translational modifications, disulfide
bridge pattern and quaternary structure (Figures 1B–D and
Supplementary Tables 1, 2). The deduced disulfide bridge
pattern and a homology search conducted with a preliminary
model of FPc13 showed that residues 28–76 folds into a TGFβ
binding (TB) domain (Supplementary Figures 1A–D) and
not a truncated thrombospondin repeat as earlier proposed
(17). The six thrombospondin repeats located after the TB
domain adopt the expected fold with three strands A, B, and C
(Supplementary Figure 2A). Whereas, strands B and C at the
C-terminal end of each TSR form an antiparallel two-stranded
β-sheet, the A strand containing the WxxWxxWxxCxx(S/T)C
motif is rippled due to the presence of two residues between
each tryptophan. These tryptophan side chains are stacking with
interdigitating arginine side chains from strands B and C as
observed for other TSRs (36). Two surfaces in each TSR can be
defined; a convex surface containing the Trp-Arg stack and a
weakly concave surface opposite to the Trp-Arg surface.
FPc has an overall shape of an elongated closed triangle
formed by the TB domain and TSR1 from one FP monomer
and TSR4, TSR5, and TSR6 from the second monomer
(Figures 1C,D). From this triangle the N-terminal end of TSR4
extends as a short arm whereas TSR2 and TSR3 form a
long extended arm. In the FPc structure, Pro255 at the C-
terminal end of TSR3 and Val256 at the N-terminal end of
TSR4 are separated by 136 Å reflecting that they come from
two different FP monomers. Compared to TSR1-4, TSR5-6 are
unusual. In TSR5, instead of having three residues between the
two cysteines in the WxxWxxWxxCxx(S/T)C motif and an O-
linked fucose-glucose disaccharide as in TSR1-4 (see below),
an ordered non-glycosylated loop (called the “thumb” below)
is formed by residues 328–336 that protrude at the concave
face of TSR5 at its C-terminal end (Figure 1E). TSR6 is even
more unique due to 31 residues inserted between the Cys407-
Cys439 disulfide bridge connecting the B- and C-strands. The
TSR6 insert folds back over TSR5 and extends with a hairpin like
loop (termed the “index finger”) together with the TSR5 thumb
loop at the concave face of TSR5 (Figure 1E). As compared
to the other neighboring TSR-TSR interfaces in FP, the TSR5-
6 domain interface is unusually large (977 Å2). It is centered
on a hydrophobic core formed by highly conserved residues
from both repeats (Figure 1E). The numerous TSR5-TSR6
interactions support a rigid orientation between the two TSRs
which is strongly bend compared to other pairs of neighboring
TSRs in FP.
The FPc and FPc13 structures reveal hinges at the TSR1-
TSR2 and TSR4-TSR5 junctions. At the TSR1-TSR2 interface
a disulfide bridge is formed between Cys132-Cys170 located in
TSR1 and TSR2, respectively. Anyway, this disulfide does not
prevent flexibility at the TSR1-TSR2 junction as the rotation of
TSR2 relative to the TB-TSR1-5-6 triangle differ by 34◦ between
the two structures (Figure 1D and Supplementary Figure 1E).
In contrast, for TSR4 we only observed 6◦ difference in the
orientation relative to the triangle, but weak electron density
for the N-terminal end of TSR4 as compared to its C-terminal
end suggests that TSR4 may have some internal flexibility
also, possibly due to the presence of only two tryptophans in
its WxxWxxWxxCxx(S/T)C motif (Supplementary Figure 2A).
Since we do not observe TSR3 in the C3bBbSCIN-FPc complex
(see below), we suggest that a hinge is located at the TSR2-
TSR3 junction as well. The compact shape of the FP monomer
associated with the E244K mutation (12) furthermore requires a
hinge at the TSR3-TSR4 junction. This suggest the presence of
the following four hinges between TSRs in FP: TSR1-2, TSR2-3,
TSR3-4, and TSR4-5.
A simple model of the FP dimer in concordance with classic
EM pictures of FP oligomers (16, 18) can now be constructed
starting from the FPc structure. First, the TSR3 is rotated to
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obtain a less bend orientation relative to TSR2. Then the TSR3 C-
terminus is placed close to the N-terminus of TSR4 in a second
FPc molecule while the TB-TSR1-TSR5-TSR6 triangle remains
unchanged. The resulting idealized dimer model presented in
Figure 1F has 2-fold symmetry, but FP oligomers may well be
dynamic and non-symmetric. It is furthermore conceivable that
by combinations of rotations at the four TSR-TSR hinges, one
may model structures resembling the trimers and tetramers also
known from EM micrographs (16). The dimer model displayed
in Figure 1F has a maximum extent of 23 nm which is in
reasonable agreement with the 25 nm including a hydration
layer estimated by small angle X-ray scattering. A slightly larger
dimer model may also be obtained by further rotation of TSR4
relative to TSR5. In summary, our crystal structures reveal a
stable core formed by the TB domain and three TSRs, whereas
flexibility at four TSR-TSR junctions allows for the formation of
extended FP oligomers where the structural cores are separated
by thrombospondin repeats 2, 3, and 4.
The Post-translational Modifications of FP
Whereas, the disulfide bridge pattern in six thrombospondin
repeats were those expected, the three cysteine bridges 32–56,
43–73, and 57–75 in the N-terminal TB domain differed from
those annotated in UNIPROT. We therefore confirmed the
disulfide bridge pattern by two orthogonal techniques. First,
an anomalous Fourier map calculated from data collected at
λ = 2.48 Å (Supplementary Figure 1B) confirmed the three
disulfide bridges. Second, we also isolated the TB domain
from the TB-TSR1-TSR2 fragment of FPc13 by reverse
phase chromatography and performed mass spectrometry
analysis. This revealed ions representing disulfide-linked
peptides confirming the observed disulfide arrangement
(Supplementary Figure 1F). One peptide obtained by trypsin
digestion contained an ion of m/z 5112.5, which corresponds
to a complex composed of the 4 disulfide-linked tryptic
peptides spanning the N-terminal region of FP (m/zcalc
5112.8) (Supplementary Figure 1F). The TB domain disulfide
bridge pattern was furthermore validated by the absence of
masses representing peptides connected by Cys32-Cys72/75
(Supplementary Figure 1F, green and yellow; m/zcalc 2620.9)
and Cys43-Cys56/57 (Supplementary Figure 1F, red and blue;
m/zcalc 2492.9). In summary, comprehensive structural data and
mass spectrometry analysis demonstrated for the first time that
FP residues 28–76 fold into a TB domain.
FP contains a wealth of posttranslational modifications
with sugars also shared by other thrombospondin repeat
containing proteins. Up to three tryptophans in the
WxxWxxWxxCxx(S/T)C motif in each TSR domain may
be modified with a mannosylation through a covalent bond
between the tryptophan indole CD1 atom and the C1 atom of
the mannose. For both FPc and FPc13 the electron densities are
consistent with the 14 mannosylations annotated in UNIPROT,
but in addition we observed significant mannosylation at
Trp202 confirming a recent MS study (9). As an example,
the electron density for the three mannosylations in TSR2 is
displayed in Supplementary Figure 3A. The electron density
is not equally strong for all mannosylations and it cannot be
excluded that some of these have only partial occupancy. We
modeled the Trp-bound α-mannosyl residues in the 1C4 chair
conformation as it consistently fitted the density better than
the default favored 4C1 pyranose conformation. In addition,
NMR measurements on a model mannose-indole compound
support the 1C4 chair conformation for the α-mannosyl linkage
(37). We observe a preferred orientation of the pyranose
ring where the 2-OH interacts with the tryptophan main
chain amide (Supplementary Figure 3B), and the endocyclic
pyranose oxygen and the 6-OH in many instances engage in
hydrogen bonding with an arginine side chain stacking with
the tryptophan.
In addition to tryptophan mannosylations, we also observe
clear density for four O-linked fucosyl-glucosyl disaccharides
linked to the threonine/serine side chain located at C-
terminal end of the concave face in TSR1-4. In the TSR1
domain the O-linked glycosylation on Thr92 points toward
TSR2 and shields the Cys93-Cys133 disulfide from solvent
(Supplementary Figure 1E). In TSR2, Thr151 is modified and
also in this case the disaccharide shields the equivalent Cys152-
Cys190 disulfide but it also engages in a hydrogen bond with
His193 in TSR3. In TSR3, the disaccharide linked to Ser208
likewise shields the Cys209-Cys254 disulfide. In TSR4, Thr272
carries the disaccharide that again shields the disulfide bridge
Cys273-Cys312 but in addition forms a hydrogen bond with
Asn59 in the TB domain. In summary, all the expected C-linked
and O-linked posttranslational modifications are observed and
well-ordered in our structures. The O-linked glycans appear
to have a common structural function in protecting a nearby
conserved disulfide bridge.
Structure of the FP Convertase Complex
and the Mechanism of AP Stimulation
We previously presented (12) a molecular envelope of FP based
on omit density calculated from diffraction data extending to
6 Å from crystals containing the complex between FPc and
the AP C3 convertase C3bBb and the small Staphylococcus
aureus complement evasion protein SCIN (38). As previously
described, the catalytic Bb subunit attaches to C3b through a
Mg2+ dependent interaction in which the very C-terminal end of
C3b is recognized by the von Willebrand type A (vWA) domain
in the catalytic subunit Bb. Two molecules of SCIN stabilizes a
convertase dimer tightly packed around a 2-fold rotation axis
by simultaneously interacting with multiple regions in both
C3b and Bb (Supplementary Figures 4A,B). In contrast to the
spontaneous dissociation of the C3bBb convertase occurring
within minutes, this dimeric SCIN stabilized convertase is stable
for weeks but also incapable of binding substrate and turn over
C3 (38). To obtain an improved understanding of the FP-C3bBb
interaction we here also obtained diffraction data extending
to 6.2 Å resolution for the complex between C3bBb, SCIN,
FPc13, and the FP specific non-inhibitory nanobody hFPNb1
(Supplementary Figures 4C,D). Although the resolution was
low for both FP-convertase structures, the quality of the electron
densities calculated without FP contribution was good due to
high solvent contents, 2-fold non-crystallographic symmetry and
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multi crystal averaging between the two crystal forms. We then
fitted the relevant parts of the FPc structure into the electron
densities of both C3bBb-SCIN complexes (Figures 2A–C and
Supplementary Figures 4A–D) and the structure of hFPNb1
determined at 1.3 Å resolution into the hFPNb1-FPc13-
C3bBb-SCIN complex (Supplementary Figures 5A–C). After
this, minor rebuilding and refinement was performed to
obtain the final models. For the FPc-C3bBb-SCIN complex
(Supplementary Figures 4A,B) we observed weak electron
densities for FP TSR2 and TSR3 and for this reason we
did not model them. With respect to the hFPNb1-FP13-
C3bBb-SCIN structure (Supplementary Figures 4C,D),
TSR2 could be modeled in one of the two complexes
(Supplementary Figure 4H). The epitope of the hFPNb1
nanobody appears be located within residues 267–281 at the
end of FP TSR4 located close to TSR5 and the TB domain,
and all three complementarity determining regions (CDRs)
seem to contribute to the paratope (Supplementary Figure 5A).
In accordance with its lack of inhibition of the alternative
pathway in C3 deposition assays (Supplementary Figure 5D),
hFPNb1 is located 25 Å from the C3b and 58 Å from Bb
Supplementary Figures 4C,D). One proof of the reliability of
our convertase-FP structures was obtained when we mutated
three residues in the hFPNb1 CDR3 predicted from the
hFPNb1-FPc13-C3bBb-SCIN structure to be important for
FP recognition. Affinity measurements for the FP-hFPNb1
interaction performed with bio-layer interferometry (BLI)
demonstrated that hFPNb1 had been placed in an overall
correct position in the electron density at 6.2 Å resolution
(Supplementary Figure 5E).
There are small differences between the four copies of
the C3bBb-FP complex present in the two crystal forms
(Supplementary Figure 4G). They differ by 3◦ rotation of the
Bb von Willebrand type A (vWA) domain relative to C3b
and by 7◦ rotation of FP relative to C3b, but crystal packing
may contribute. Due to the resolution of these structures, the
interactions discussed below must be considered putative, but
at an overall level the model is likely to be reliable, especially
due to the resolution of the input models (2.8 Å for FPc, 1.3 Å
for hFPNb1, and 3.9 Å for C3bBbSCIN). We present here the
C3bBbSCIN-FPc structure, and as we previously suggested (12)
themajor FP binding site is located within C3b residues Glu1634-
Phe1659 encompassing the small α2 helix (1,634–1,638) and
following large C-terminal α3 helix (1,640–1,659) in the C345c
domain of C3b. Apparently there is also a smaller contribution
to the convertase FP site from the Bb vWA domain. These
C3bBb elements are recognized by the concave face of FP TSR5
including the “thumb” loop together with the TSR6 “index finger”
loop (Figures 2D–G, Supplementary Figures 2B–D, 4E,F). One
major FP-C3b contact occurs close to Bb and appears to involve
a mixture of polar and non-polar interactions. A saddle shaped
surface formed by TSR5 including the thumb loop and the
TSR6 index finger surrounds the surface exposed non-polar
C3b side chains of Val1657, Val1658, and Phe1659 (Figure 2D,
Supplementary Figures 2B–D and Supplementary Table 3).
Direct FP-Bb interactions appear to be limited but the strictly
conserved FP Arg329 side chain may form contacts with the
main chain of Bb Leu349 while the Bb side chain Tyr317
appears to reach out toward Met420 and Glu422 in the TSR6
index finger. Since the coordination of the Mg2+ ion in the Bb
metal ion dependent adhesion site (MIDAS) by the C-terminus
carboxylate from C3b is crucial for the C3b-Bb interaction, FP
mediated stabilization of the AP C3 convertase may be explained
by the observation that the three C-terminal residues of C3b
Cys1661-Asn1663 are sandwiched between the FP TSR5 thumb
loop and Bb (Figure 2E). The second major point of FP-C3b
contact appears to be mediated mainly by electrostatic and
other polar contacts and involves the C3b α2 helix and the
N-terminal residues in the α3 helix. Specifically, this interface
contains FP residues organized around the side chain of Trp318
including Arg353 and Arg359 and polar C3b residues located
between Glu1634 and Gln1647 (Figure 2F). These polar C3b
residues include multiple negatively charged side chains, and the
electrostatic potentials of the interacting C3b and FP surfaces
suggest that ionic interactions play a major role at this contact
point. In summary, the FP binding site on the AP C3 convertase
is dominated by C3b residues located in two separate patches.
The C-terminal Asn1663 in C3b that coordinates the Mg2+ ion
in the Bb MIDAS is likely to be considerably less mobile in the
presence of the thumb loop from FP TSR5. In combination with
the few putative direct FP-Bb contacts, such stabilization may
underlie the reduced rate of Bb dissociation from C3b in the
presence of FP.
An FP-convertase model should rationalize why native C3
does not bind FP despite that the binding site is located entirely
in the C3b C345c domain, which at first glance has a very similar
structure in C3 and C3b. We superimposed this domain from
six C3b containing structures and two structures of native C3
including a new structure of C3 bound to the hC3Nb1 nanobody
(Supplementary Table 2) on residues 1,544–1,610. This revealed
a striking difference in the α2-helix and the loop connecting
it to the α3-helix (Figure 2H). According to our convertase-
FP structure contacts from this region are likely to be formed
with FP TSR5 residues Arg351-Arg359 (Figure 2F), and if the
C3 conformation of this region was adopted these contacts
could probably not be formed. The α3 helix as such is also
slightly rotated when comparing C3b and C3, resulting in a small
difference between the two states in the location of Phe1659 at the
heart of the non-polar C3b-FP interaction.
We also investigated whether the dynamic properties
of the FP binding regions differed between C3 and C3b
by conducting molecular dynamics simulations of the two
full proteins (Figure 2I and Supplementary Figure 6). A
comparison of the dynamic properties of the putative FP binding
regions revealed a clear difference between the two states of
the C345c domain, especially around residues 1,580–1,595,
1,609–1,615, and 1,635–1,645 including the α2-α3 region
presumably involved in FP binding (Supplementary Figure 6A).
Altogether, our analysis indicates that the FP preference for
C3b is mainly due to a conformational difference in and
around the C345c α2-helix supplemented with an increased
mobility of this region. These changes may originate from the
anchor region located immediately prior to the C345c domain
which undergoes a conformational rearrangement in terms
of both location and secondary structure upon conversion
of C3 to C3b (39). Importantly, the high overall mobility of
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FIGURE 2 | Structure of the FP bound AP C3 convertase. (A) Outline of the FP bound convertase shown in a cartoon representation. In FP only the TB domain, TSR1
and TSR4-6 were modeled. The SCIN protein used to stabilize C3bBb is not shown. (B) A 2mFo-DFc omit map contoured at 1σ in which FP TSR5, the FP TSR6
index finger, and all associated glycosylations were omitted from map calculation. Unambiguous density is observed for the index finger and its Asn-linked glycan.
(C) Close-up of the region outlined in panel A with a dotted rectangle containing the FP-C3b interface. The α2- and α3-helices and their connecting loop in the C3b
(Continued)
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FIGURE 2 | C345c domain are recognized by the concave face of FP TSR5. (D–F) Details of the FP-C3 convertase interface with selected residues shown as sticks.
(D) Outline of the interaction between the thumb and index finger of TSR5 and TSR6, respectively, and the α3-helix of C3 C345c. The C-terminal of C3 C345c
protruding from the α3-helix completes the coordination of the Mg
2+-ion present in the MIDAS of Bb. (E) The Bb vWA-C3 C345c interface, suggesting the
importance of the FP TSR5 thumb in stabilizing the interaction. (F) The interaction surface formed between TSR5 and the C3 C345c α2 and α3 helix. A large number
of basic residues in TSR5 are presumably interacting with the acidic α2 helix in C3b. (G) Footprint of FP on the AP C3 convertase (Top) or AP C3 convertase on FP
(bottom). The footprint of FP on C3b and Bb is colored blue, whereas the footprint of C3b and Bb on FP is colored gray and orange, respectively. (H) Superposition of
six C3b structures (gray) and two C3 (pink) structures on the central β-sheet of the C3 C345c domain. This demonstrate a clear difference around the α2-helix which
may explain the specificity of FP for C3b. (I) Residue fluctuations of the C345c domain of C3b (gray) and C3 (pink) during molecular dynamics simulations. The
thickness of the residues is proportional to the root mean square fluctuations in a 1 µs simulation.
the C345c domain in C3b was confirmed by our simulation
(Supplementary Figure 6B) reproducing a well-established
property of this domain observed in crystal structures. This
mobility of the domain may facilitate its search for a C3b binding
site in a nearby FP molecule.
Validation of the FP-Convertase
Interactions
Identification of the FP regions mediating oligomerization in
our structures led us to hypothesize that a monomeric FP
equivalent to FPc could be assembled correctly in mammalian
cells if the TB-TSR1-TSR2-TSR3 head and the TSR4-TSR5-
TSR6 tail fragments were expressed as separate polypeptides
(Figure 3A). As our structures did not indicate any role for TSR2
and TSR3 in FP oligomerization and convertase interaction, we
also deleted TSR2-TSR3 or TSR3 from the head fragment and
observed that complexes between the intact tail fragment and
these two truncated head fragments indeed were secreted. The
resulting purified FPht13 and FPht12,3 were active in forming
stable complexes with the proconvertase C3bB in size exclusion
chromatography (Figures 3B–D). In the light of these data and
our structures of the FP-convertase complex we conclude that
FPht12,3 is the minimal FP monomer that is functional in
convertase binding. These results are in agreement with the fact
that active oligomers are formed by FP lacking TSR3 (19).
The head-tail expression system only generates FP monomers
and therefore uncouples the effect of FPmutations from oligomer
distribution. This is important as FP activity in complement
activation assays and sensor-based interaction measurements
crucially depends on the oligomer distribution (12).We therefore
used FP variants produced in the head-tail system with 1–2
residues mutated to alanine to validate the contacts between
FP and C3b inferred from our convertase structure and
the human FP deficiency mutants Q343R and Y414D (see
below). All FPht variants were purified to high homogeneity
and did not show signs of aggregation suggesting proper
folding. In BLI experiments with immobilized C3b all the FPht
mutations resulted in decreased binding to C3b (Figures 3E,F).
Severe defects were observed for Q343R, Y414D, R329A, and
R353A. Wild type (WT) FPht had a dissociation constant
KD = 0.3µM for C3b, mutation of Arg353 increased this to
1µM whereas the two FP deficiency mutants gave KD values
of 4–5µM. (Figures 3G,H).
Based on the proximity of FP TSR5-6 to the Bb vWA domain
and FB sequence conservation we also prepared a variant with
348-KLK-350 mutated to alanine in a FB molecule already
carrying the D279G mutation giving stronger C3b binding
(40) and S699A rendering it proteolytically inactive. We then
bound WT FPht to a hFPNb1 coated BLI sensor and measured
binding of C3b and the AP C3 proconvertases assembled with
the FB variants 348-KLK-350 and 348-AAA-350. Significantly
less binding of the C3bB AAA proconvertase as compared to
the C3bB KLK was observed (Figure 3I), supporting a role
of these residues in the FB-FP interaction within the AP C3
proconvertase. The decreased binding of FB AAA is not due to
decreased formation of the C3bB proconvertase itself, because
when we measured binding of FB KLK and FB AAA directly
to immobilized C3b no significant differences between the
two FB variants were observed (Figure 3J). Altogether, these
biophysical data supports our structure-based mapping of the
C3b interacting residues in FP and provides further evidence for
a direct FP-FB interaction in the proconvertase. In combination
with our ability to identify the hFPNb1 residues in contact
with FP, these results also confirm the reliability of our X-ray
structures of convertase-FP complexes.
FP Inhibits FI-FH Mediated Degradation of
C3b to iC3b
Cofactor dependent degradation of C3b by factor I (FI)
represents an important regulatory mechanism of the alternative
pathway on host tissue (41). Factor H (FH) is a soluble
cofactor that through interaction with surface glycan allows
C3b degradation by FI, reviewed in Blaum (42). Farries et al.
showed that the presence of FP inhibited FI interaction with
erythrocyte bound C3b and made erythrocyte lysis less sensitive
to FI, indirectly suggesting that FP inhibits C3b degradation due
to FI-FP competition as an additional mechanism for stimulating
AP activity (43). Our structures suggests a strong overlap between
the binding sites for the FI FIM domain (44) and FP on the C3b
C345c domain (Figure 4A). To analyze the FP-FI competition
in a minimal system we immobilized mini-FH (22) on a BLI
sensor to confirm that C3b can bind mini-FH and dimeric FP
simultaneously (Figure 4B). Next, we investigated the effect of FP
on FH-assisted FI degradation of C3b in a minimal system where
we immobilized C3b on streptavidin beads and followed its FI
degradation to iC3b with FH as cofactor (Figures 4C,D). In the
presence of a mixture of trimeric and dimeric FP, we observed a
significantly slower formation of iC3b in agreement with a direct
competition between of FP and FI. These and prior data (43)
confirm the importance of the interaction between the FI FIM
domain and the C3b C345c domain (44) and are consistent with
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FIGURE 3 | Validation of the FP-C3 AP convertase and definition of a minimal FP fragment. (A) monomeric FP head-tail (ht) proteins created by co-expression from
two open reading frames. (B) Chromatograms from analytical SEC analysis of FPc (blue), FPht13 (red), FPht12,3 (green). (C) SEC analysis of AP C3 proconvertase
formation using FPc (blue), FPht13 (red), FPht12,3 (green), or no FP (orange) demonstrating that all the tested FP monomers formed a stable complex with the
proconvertase. (D) SDS-PAGE analysis of the peak fractions from the SEC runs in panel C. (E) Sensograms showing binding of WT and mutated FPht to a C3b
coated sensor. (F) Quantification of FPht binding expressed in % of the WT signal. The signal corresponds to the average signal taken from 80 to 120 s in two
(Continued)
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FIGURE 3 | independent experiments. The standard deviation is represented by error bars. (G) Sensograms obtained in concentration series ranging from 1,852 to
29 nM for FPht, FPht R353A, Q343R, and Y414D. The KD obtained from steady state analysis of the data is indicated in the figure. (H) Steady state analysis of the
data shown in panel G. The measured Req (average signal from 40 to 60 s) is shown as a function of FPht concentration. (I) Sensograms for binding of C3b, C3bB
KLK, and C3bB AAA to a FP coated sensor. The C3bB KLK complex binds more strongly to FP than C3bB AAA. (J) Sensograms for binding of FB KLK and FB AAA
to a C3b coated sensor demonstrating that the effect of the FB AAA mutation shown in panel I is not due to decreased C3b binding.
FIGURE 4 | FP competes with FI but not FH for C3b binding. (A) Superposition of the C3bBbFP structure and the C3b-FH-FI structure (PDB entry 5O32), showing
that FI and FP have overlapping binding sites on surface of the C3b C345c domain. C3b is shown in gray, FI is shown in green and FP is shown in blue. (B) BLI
binding experiment demonstrating that FP and miniFH can interact with C3b simultaneously. The sensograms for the association phase (0–60 s) and dissociation
phase (60–120 s) are shown for the interaction of a miniFH coated sensor with either C3b (brown), FP (red) or C3b preincubated with FP (blue). (C) SDS-PAGE
analysis of FH-assisted FI proteolysis of biotinylated C3b on streptavidin beads either in the presence (+FP) or absence (–FP) of FP. Conversion of C3b to iC3b is
observed to be decreased in the presence of FP. (D) A quantification of the assay shown in panel C. The ratio between the intensities of the α’ and streptavidin bands
from three independent experiments is used as a measure of uncleaved C3b. Error bars indicate the standard deviation between the three experiments. The cleavage
was fitted with a first-order exponential decay.
the observed effects of membrane cofactor protein on C3bBb
decay and C3b degradation in the presence of FP (18).
The FP Oligomerization Interfaces
Our structures offer structural insight into how FP oligomers
are maintained through two major contacts between the TB-
TSR1 from one monomer and TSR4-6 from a second monomer.
The TB domain recognizes the TSR4 domain from another
monomer while the concave face of TSR1 from one monomer
interacts with a short C-terminal extension of TSR6 from
the second monomer (Figures 5A,B). Analysis of the interface
between the two chains reports a total interface of 1,109
Å2 with 665 Å2 for the TSR1-TSR6 interface and 444 Å2
for the TB-TSR4 interface. The TSR1-TSR6 interface is also
the more hydrophobic according to PISA (45). The TB-TSR4
interface is centered on Leu58, Cys312, and Leu275 with smaller
contributions from Leu47, Phe62, and Ile305. Nearby, a salt
bridge between Arg76 and Glu317 links the TB domain with
TSR5. The TSR1-TSR6 interface is centered on the contacts
formed by Pro399 with Leu124, the stacking of the Trp122 with
the Cys395-461 disulfide and hydrogen bonds between Ser97-
Leu456 and Ser90-His457. To validate the two oligomerization
interfaces, we established a cellular assay taking advantage of
the fact that secretion of the tail fragment depends strictly
on the expression of the head fragment. Hence, secretion of
FPht variants could be followed by detection of the His-tag
present on the FP tail. To challenge the non-polar contacts
observed between the TB domain and TSR4 we mutated Leu47,
Leu58, and Leu275 to alanine. Mutation of Leu58 and Leu275
had significant effects and in the triple mutant secretion was
severely affected (Figure 5C). Mutation of Leu456 to valine
at the TSR6-TSR1 interface had a modest effect in this assay
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FIGURE 5 | Structure of the FP oligomerization interface and analysis of its stability. (A) Outline of the interface between TB and TSR4 of FP. Important residues are
shown in an all-atom stick representation. The O-linked glycan on T272 is directly involved in the interaction of TSR4 with the TB domain through a hydrogen bond
(dotted line). (B) As panel A but presenting the interface between TSR1 and TSR6. (C)Western blot analysis of cell supernatants obtained with different FPht mutants.
To account for differences in total amount of cells a western blot of GAPDH from the cell pellet was performed using the same amount of sample volume.
despite its coupling to inflammatory bowel disease (46) whereas
there was a severe defect in FP secretion for the triple
mutant L47A/L58A/L456V affecting both the TB-TSR4 and the
TSR6-TSR1 interaction (Figure 5C). Overall, these mutations
confirmed the two observed oligomerization interfaces.
Naturally Occurring FP Mutants Disrupting
Function
Our results offer a structure-based explanation for lack of
AP activity caused by FP deficiencies. In type I deficiency
there is no FP secreted most likely due to intracellular quality
control triggering degradation of truncated or misfolded FP. The
mutations G298V, W321S/G, and R346C cause type I deficiency
(5, 47, 48). The presence of a valine side chain instead of Gly298
would prevent insertion of Trp260 in the Trp/Arg stack of TSR4
possibly leading to incorrect folding of TSR4 and a decreased
stability of the TB-TSR4 interaction in the oligomer. Disruption
of the Trp stack in TSR5 is also a likely consequence of the
Trp321Ser/Gly as well as the mutation Arg346Cys.
In type II deficiencies the FP serum level is abnormally low
and oligomerization is affected. We identified a novel type II FP
deficiency in a 1-year old boy who was hospitalized after 2 days
of abdominal pain, vomiting, severe neurological deterioration
and appearance of purpuric skin eruption associated with fever.
Two days after the onset of the first symptom, the patient
was admitted to the emergency department with hemodynamic
instability with tachycardia, severe hypotension together with an
extensive and necrotic purpura. Despite massive IV fluids and
adrenaline administration, the patient died 24 h after admission.
Blood culture and skin biopsies came back positive for Neisseria
meningitidis serogroup W135. A screening for FP deficiency
revealed one asymptomatic uncle. The mother, the grandmother
and a still unborn child carried the genetic trait of the pathogenic
allele (Figure 6A). The causative Cys32Tyr mutation disrupts
one of the three disulfide bridges in the TB domain which may
lead to a defect in the TB-TSR4 head-tail interaction due to
the vicinity of Cys32 to TSR4 (Figure 5A). Analysis by head-
tail expression also showed very low levels of secreted FP C32Y
confirming this model (Figure 5C).
We previously described how another type II deficiency
caused by the Glu244Lys mutation in TSR3 results in very
low AP activity, and recombinant FP E244K is secreted almost
exclusively as a monomer with a compact structure (12). Our
FPc crystal structure reveals that Glu244 interacts electrostatically
with Arg220. To analyze whether the charge reversal of glutamate
to lysine underlies the altered oligomer distribution we compared
the oligomer distribution for three additional mutations to
those of WT FP and FP E244K. The E244R variant was like
FP E244K and was secreted almost exclusively as monomers,
while mutation to alanine, or glutamine resulted in an oligomer
distribution resembling that of wild type recombinant FP
(Figure 6B). This suggests that charge reversal mutations at
residue 244 destabilizes Arg220 and thereby presumably the
Trp/Arg stack containing Arg220 (Figure 6C). This most likely
translates into incomplete folding and degradation explaining
the low abundance of FP in the plasma of E244K carriers (12).
The failure of FP E244K oligomer formation is more difficult to
rationalize from the structure.
Another example of type II deficiency is the Arg100Trp
substitution where a tryptophan takes the place of an arginine
in the TSR1 Trp/Arg stack. This substitution may weaken the
nearby TSR1-TSR6 interaction in one of the two oligomerization
interfaces (Figure 5B) rationalizing the low serum level and
altered oligomer distribution (49). Mutation of Gln343 to Arg
also results in type II deficiency with a shift in the oligomer
distribution toward dimers (49). Gln343 is located at the C3b
binding site and our binding studies showed that its mutation
to the larger arginine significantly decreases the FPht affinity for
C3b (Figures 3E–H). There is one known type III deficiency,
the Tyr414Asp mutation where serum FP level and oligomer
distribution is normal but AP activity is absent and FP binding
to immobilized C3bB and C3bBb is very low (50). Using
BLI, we confirmed a decreased FPht Y414D affinity for C3b
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FIGURE 6 | Molecular basis for naturally occurring FP deficiencies. (A) Pedigree of the FP C32Y deficiency family. Plasma FP levels for the patient were below 10% of
normal. AP50 and CH50 were determined for the son and showed normal CP but impaired AP activity. The FP level of his heathy uncle who carries the FP pathogenic
variant was below 10% of normal value without detectable impairment of the CP and AP activities. His father as well as the heterozygous mother and grandmother
both carrying the FP mutation exhibited normal complement activity profiles (AP50/CH50) and FP serum levels. (B) Oligomer distribution obtained with WT FP and
variants carrying a mutation at residue 244. Recombinant FP was affinity purified on hFPNb1 beads, fractionated by SEC and the resulting fractions were analyzed by
western blotting. (C) Outline of the TSR3 tryptophan-arginine stack demonstrating how glutamate 244 and Arg220 interact electrostatically. (D) Close-up view of Y414
and surrounding residues neighboring the thumb and index finger in TSR5 and TSR6, respectively. Y414 is stacking between E339 and P412 and is located in a
hydrophobic pocket harboring F431 and Y371.
(Figures 3E,H). The structure rationalizes these results as Tyr414
is located immediately before the index finger loop in TSR6 and
neighbors the thumb loop in TSR5, and both loops are part of
the C3b binding site and also face Bb (Figure 6D). A mutation
to aspartate is likely to lead to repulsion between an aspartate in
position 414 and Glu339 and thereby disturb the structure of the
index finger loop involved in convertase interaction. In summary,
our structures of FP and the FP-convertase complex enable an
understanding of the functional defects associated with novel and
known FP deficiencies not caused by premature stop codons.
DISCUSSION
The atomic structures presented here represents a quantum
leap in our understanding of how the function of FP relates
to its structure. Although electron microscopy and our first
crystallographic study clearly revealed the eye-shaped vertex
interacting with the C3 convertase, essential questions including
which TSRs form the vertex, what is the fold of the N-terminal
region, how do two FP molecules come together and form the
vertex structure, and which structural features allow FP to form a
spectrum of oligomers could not be answered (12, 18). All these
questions are now settled by our structures.
FP Stimulation of the Alternative Pathway
The primary biological function of FP is stimulation of AP
convertase activity and our structures now unambiguously define
the C-terminal domain of C3b as the primary binding site
supplemented with a contribution from Bb. A far more extensive
interaction of FP with the Bb vWA domain inferred from
negative stain EM (18) is not supported by our structures. In our
first crystallographic study we presented an electron density for
the core part of FP at 6 Å resolution bound to the convertase.
But in the absence of an atomic structure of FP, we could only
identify in an overall manner the region in C3b interacting with
FP. Furthermore, we could not identify which parts of FP that
were in direct contact with C3b and Bb although we did suggest
that TSR5 plays a key role (12). In the presence of the atomic
structure of FPc we can now present a much improved model
for the FP-convertase interaction. It is now clear that the thumb
loop in FP TSR5 contributes to a binding pocket for the C-
terminus of C3b and that the index finger loop FP TSR6 is likely
to interact directly with FB and Bb.We also conclude based on
structural comparisons and molecular dynamics simulations that
the specificity for C3b over C3 is primarily due to subtle structural
differences and differences in mobility in a small stretch of C3b
residues involved in FP binding.
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Our mapping of the convertase binding site to FP TSR5 and
TSR6 agrees with the properties of FP deletion mutants (19, 51),
and the epitope location of monoclonal antibodies blocking FP
activity (52). A bacterially expressed fusion protein containing
TSR4-TSR5 has been reported to act as an alternative pathway
inhibitor (53, 54). Our structures argue that in the absence of
TSR6, major parts of the C3b binding elements located in TSR5
of such a recombinant fragment will not be fully functional.
Furthermore, the absence of the C- and O-linked glycans that
our structures now reveal as well-ordered and interacting with
protein residues also argues that experimental data obtained
with bacterially expressed FP fragments should be interpreted
with caution.
Our structural and functional studies also emphasize that
FP contributes in at least three ways to enhance the activity of
the alternative pathway. First, there is a synergistic recruitment
of FP and FB to the AP proconvertase (12, 55, 56), but the
structural basis for this remains to be clarified, possibly there
are additional contacts between FP and FB compared to the FP-
convertase complexes. Data presented here show for the first
time that contacts between FP and the FB vWA domain are
important for FP stimulated formation of the proconvertase
(Figures 3I,J), but comparison with the structure of the FD
bound proconvertase (57) also suggests that the CCP1 domain in
FB may form direct contacts with the thumb loop in FP TSR5.
Second, our structures suggest that the slower dissociation of
the C3bBb complex in the presence of FP is due to a tighter
binding of the C3b C-terminus to the Bb MIDAS supplemented
with a few direct FP-Bb interactions. Here the thumb loop in
TSR5 appears to play a key role as it together with the vWA
domain in Bb forms a binding pocket for the C-terminal residues
in C3b. Third, our functional data and structural comparisons
(Figure 4) conclusively show that FP compete directly with FI
and thereby counteracts the most important mechanism for
negative regulation of the alternative pathway in which FH and
other complement regulators by binding to C3b create a binding
platform for FI (44, 58) enabling the irreversible C3b degradation.
FP does not directly compete with mini-FH (Figure 4B), but
by stabilizing both the proconvertase and the convertase it will
indirectlymake it harder for FH and other regulators to dissociate
FB and Bb from C3b.
Negative stain EM suggested that all the convertase binding
sites in oligomeric FP could bind a convertase simultaneously
(18) in agreement with the dimer model presented in Figure 1F,
where the two convertase binding sites are located at each
pole of the dimer. The activity of FP oligomers in erythrocyte
lysis follows the order tetramers > trimers > dimers (11),
and the FPc monomer is much less active in convertase
stabilization on erythrocytes and bactericidal activity compared
to oligomeric FP (12). We cannot exclude that the convertase
binding site we identify encompassing the concave face of
TSR5 and the index finger loop from TSR6 has a slightly
different structure in oligomeric FP. However, the flexibility
enabling FP to form the different oligomers argues that there is
no allosteric communication between convertase binding sites
within a single oligomeric FP molecule, and we suggest that the
convertase binding sites are independent. The higher activity
of oligomers could have contributions from, (i) A single FP
oligomer binding multiple activator-bound C3b molecules, (ii)
a high local concentration of C3b binding sites favoring FP
rebinding after dissociation, (iii) a defined 3D structure of the
oligomers. Our prior SPR data showed a 450x lower apparent
KD value for immobilized C3b and fluid phase oligomeric
FP as compared to the reverse geometry (12) arguing for a
contribution from multivalent binding. In contrast, binding
experiments measuring FP association to erythrocyte bound
C3bB and zymosan-C3b complexes suggested that FP oligomers
bind to a C3b coated activator in a monovalent manner (43, 55).
A better understanding on how FP oligomerization contributes to
activity may require comparison of activity in multiple functions
of natural FP oligomers with engineered oligomers formed by
multimerization of FP monomers by other means. The atomic
structures of FP also opens new opportunities for developing
much improved models of the FP oligomers based on data from
solution scattering and other biophysical techniques compared
to prior models developed previously (17) that could not take
advantage of the detailed atomic structures presented here.
Role of FP in C5 Convertases
An unresolved question concerns the role of FP for the activity of
C5 convertases. These are formed from the alternative pathway
C3 convertase C3bBb and the homologous classical pathway C3
convertase C4b2a at a high density of C3b on the activator. The
C5 convertases initiates the terminal pathway where cleavage of
complement C5 results in release of the potent proinflammatory
anaphylatoxin C5a that activate a range of cell types through
binding to the C5aR1 receptor (59). Furthermore, C5b is
generated and nucleates the assembly of the membrane attack
complex that may lyse pathogens but also host cells with defects
in complement regulation as exemplified by the lysis of red blood
cells in paroxysmal nocturnal hemoglobinuria (60). The exact
composition and structure of the C5 convertases are not clear, it
remains to be settled whether there is an additional C3bmolecule
directly associated with both C5 convertases or the role of the
high C3b density is to recruit and prime C5 for cleavage by a
C3 convertase, reviewed in Schatz-Jakobsen et al. (15). Since FP
promotes the required high C3b density through its stimulation
of the alternative pathway C3 convertase, it is not surprising
that FP deficiency or blockade inhibits the terminal pathway
(61). At the high C3b density required for formation of both C5
convertases, oligomeric FP must bind avidly. The FP stabilized
alternative pathway C3- and the C5-convertases decays by Bb
dissociation with similar kinetics (62) suggesting that FP binds
to the C3bBb part within the alternative pathway C5 convertase
as observed here for the C3 convertase. In contrast, FP binding
to C3b has been reported to inhibit the classical pathway C5
convertase activity without interfering with CP C3 convertase
activity (63) indicating that the C3b C345c domain holding
the FP binding site have a function in the CP C5 convertase
activity. Since none of the C5 convertases have been reconstituted
in a soluble format, structural insight on the function of FP
in relation to the C5 convertases may require tomograms of
vesicles onto which C3b and the convertases have been deposited
(64). Such studies may also lead to an improved understanding
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of C3 nephritic factors (C3NeFs), which are prevalent in C3
glomerulopathy (65). C3NeFs binds a neoepitope in the labile
AP convertases and prolong their half-life. FP-dependent C3NeFs
have been shown to stabilize C5 convertases (66) underscoring
the role for FP in C5 convertase function.
Pattern Recognition and NKp46
Recognition
In contrast to the convertase related functions, the role of FP
as a C3b independent pattern recognition molecule are still
unclear. FP has been proposed to bind directly to pathogens,
activated platelets and apoptotic/necrotic host cells and thereby
recruit fluid phase C3b or the C3 tick-over product C3-H2O
and initiate alternative pathway amplification on the FP binding
pattern, reviewed in Chen et al. (3). Recently, C3b independent
recruitment of FP has been questioned (67), but in a C3 knockout
mouse FP was still deposited at injured glomeruli in vivo
although the responsible FP binding pattern was not identified
(68). Molecular patterns suggested to be recognized by FP
include LPS, negatively charged host glycan, zymosan, acetylated
LDL, and multiple proteins. Interestingly, our structure of
FPc hints at how FP mediates pattern recognition. Negatively
charged sulfated groups on host glycans may form electrostatic
interactions with the C-terminal end of TSR3, where two sulfate
ions are firmly bound to Arg247 (Supplementary Figure 3C). In
addition, the crystal packing of two TSR2 domains presented
in Supplementary Figure 3B illustrates the potential of the
TSR mannosylations and the surrounding residues for forming
hydrogen bonds with carbohydrate groups on host glycan or
glycosylated proteins. Another novel interesting function of FP
is the interaction with the NK cell receptor NKp46 enabling
recruitment of NKp46 presenting cells to Neisseria meningitidis
bacteria. Mice without NKp46 positive cells are less capable of
clearing this bacteria through a MAC independent pathway (69),
but the molecular mechanism behind the NKp46-FP interaction
remains unclear.
CONCLUSIONS AND OUTLOOK
This study present the first detailed structures of FP and overall
models of FP-convertase complexes. We also identify regions in
C3b and Bb interacting with FP, and we describe a minimal FP
fragment for convertase binding. Altogether, these results will
greatly facilitate the design of FP variants for in vitro experiments
and transgenic animals for the analysis of the crosstalk between
FP convertase stimulation, pattern recognition and NKp46
interaction. The structures also enable a rational approach to
answer fundamental questions regarding FP oligomerization
that remains to be addressed. Why is it advantageous to
have a polymer distribution rather than a monomeric protein
for enhancing alternative pathway activity? Is the increase in
biological activity with oligomer size solely due to an increasing
number of FP subunits or is there a structural component?
In a translational perspective, the interest in therapeutic
modulation of the complement system is steadily increasing due
to the association of excessive complement activation triggering
inflammation and tissue damage in eyes, kidneys, skin, brain and
the vasculature, reviewed (70). The successful blockade of the
terminal pathway has provided proof-of-concept for therapeutic
complement inhibition, but blocking of the upstreamC3 cleavage
by the alternative pathway convertase stimulated by FP could
be an alternative strategy. There have been developed a large
number of AP convertase inhibitors targeting in particular
C3 and Factor D, but monoclonal antibodies acting as FP
inhibitors have also been described, reviewed in Chen et al.
(3) and Morgan and Harris (14). The therapeutic potential
in FP inhibition has been demonstrated in animal models of
arthritis, atypical hemolytic uremic syndrome and paroxysmal
nocturnal hemoglobinuria (61, 71, 72). The structures of FP and
its convertase complexes offer a much improved foundation for
development of FP inhibitors as they pinpoint three-dimensional
epitopes and pockets on FP, C3b, and FB that may be targeted for
development of specific modulators of the alternative pathway.
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